文献速递肝病

肝硬化患者肝脏SARS-CoV-2进入受体与促炎细胞因子表达增加

Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-09-02

本文报告肝硬化患者感染SARS-CoV-2后死亡率显著高于无肝硬化者,且晚期肝硬化(Child-Pugh B和C)死亡率更高。近半数感染SARS-CoV-2的肝硬化患者发生急性失代偿,包括慢加急性肝衰竭(ACLF)。基线肝失代偿是COVID-19患者全因死亡的独立预测因素,失代偿期肝硬化合并COVID-19预后差,总死亡率超过30%。

要点

  • 肝硬化患者感染SARS-CoV-2后死亡率显著高于无肝硬化者。
  • 晚期肝硬化(Child-Pugh B和C)患者死亡率更高。
  • 失代偿期肝硬化合并COVID-19总死亡率超过30%。

核心结论

  • 肝硬化患者感染SARS-CoV-2后死亡率显著高于无肝硬化者,晚期肝硬化患者死亡率更高。
  • 近半数感染SARS-CoV-2的肝硬化患者发生急性失代偿,包括ACLF。
  • 基线肝失代偿是COVID-19患者全因死亡的独立预测因素。
  • 失代偿期肝硬化合并COVID-19预后差,总死亡率超过30%。

主要发现

  • 肝硬化患者感染SARS-CoV-2后死亡率显著高于无肝硬化者。
  • 晚期肝硬化(Child-Pugh B和C)患者死亡率更高。
  • 近半数感染SARS-CoV-2的肝硬化患者发生急性失代偿,包括ACLF。
  • 基线肝失代偿是COVID-19患者全因死亡的独立预测因素。
  • 失代偿期肝硬化合并COVID-19总死亡率超过30%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It has been recently reported that patients with cirrhosis have significantly higher mortality following severe acute respiratory syndrome coronavrisu 2 (SARS-CoV-2) infection compared with those without.1,2 Specifically, it was demonstrated that mortality was greater in those with advanced cirrhosis (Child-Pugh B and C), and that from cirrhotic patients experiencing SARS-CoV-2 infection, close to half suffer acute decompensation including acute-on-chronic liver failure (ACLF).2 Unfortunately, the presence of hepatic decompensation at baseline has been shown to be an independent predictor of all-cause mortality in patients with coronavirus disease 2019 (COVID-19).1 Patients with decompensated cirrhosis contracting COVID-19 have a poor outcome, with an overall reported mortality of over 30%.1.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Limon-De La Rosa N, Cervantes-Alvarez E, Navarro-Alvarez N, et al. Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis. Clin Gastroenterol Hepatol. 2021. PMID: 34481957. doi:10.1016/j.cgh.2021.08.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。